SEC Form SC 13G filed by Allakos Inc.

11/12/24 9:50:12 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ALLK alert in real time by email

SC 13G 1 filing.txt SCHEDULE 13G Amendment No.0 ALLAKOS INC COMMON STOCK Cusip #01671P100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #01671P100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 5,369,317 Item 6: 0 Item 7: 5,370,247 Item 8: 0 Item 9: 5,370,247 Item 11: 6.044% Item 12: HC Cusip #01671P100 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 5,370,247 Item 8: 0 Item 9: 5,370,247 Item 11: 6.044% Item 12: IN Item 1(a). Name of Issuer: ALLAKOS INC Item 1(b). Address of Issuer's Principal Executive Offices: 825 Industrial Road, Suite 500 San Carlos, CA 94070 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 01671P100 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 5,370,247 (b) Percent of Class: 6.044% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 5,370,247 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of ALLAKOS INC. The interest of Fidelity Advisor Biotechnology Fund, in the COMMON STOCK of ALLAKOS INC, amounted to 4,856,700 shares or 5.466% of the total outstanding COMMON STOCK at September 30, 2024. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Management & Research Company LLC * IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of ALLAKOS INC at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $ALLK alert in real time by email

Recent Analyst Ratings for

$ALLK

Date	Price Target	Rating	Analyst
1/17/2024	$6.00 → $1.50	Buy → Hold	Jefferies
1/16/2024		Overweight → Neutral	Cantor Fitzgerald
12/18/2023		Mkt Perform → Outperform	William Blair
12/8/2023	$9.00 → $6.00	Buy	Jefferies
9/27/2023	$11.00	Mkt Outperform	JMP Securities
5/12/2023	$6.00 → $9.00	Hold → Buy	Jefferies
3/7/2023	$22.00	Overweight	Piper Sandler
9/12/2022	$2.00	Neutral → Underperform	SMBC Nikko

More analyst ratings

SEC Form SC 13G filed by Allakos Inc.

Chat with this insight

Recent Analyst Ratings for $ALLK

$ALLK Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Allakos downgraded by Jefferies with a new price target

Allakos downgraded by Cantor Fitzgerald

Allakos upgraded by William Blair

$ALLK Press Releases

Fastest customizable press release news feed in the world

Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy Volunteers

Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results

Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile

$ALLK Market Insights

Live Market Insights

$ALLK Large Ownership Changes

This live feed shows all institutional transactions in real time.

Jefferies Maintains Hold on Allakos, Lowers Price Target to $1

JMP Securities Reiterates Market Outperform on Allakos, Maintains $3 Price Target

Allakos shares are trading lower. The company announced results from the single and multiple ascending Phase 1 study of intravenous AK006 in healthy volunteers.

SEC Form SC 13G filed by Allakos Inc.

Amendment: SEC Form SC 13G/A filed by Allakos Inc.

SEC Form SC 13G/A filed by Allakos Inc. (Amendment)

$ALLK SEC Filings

Allakos Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement

SEC Form 10-Q filed by Allakos Inc.

Allakos Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$ALLK Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Alexander Robert covered exercise/tax liability with 37,311 shares, decreasing direct ownership by 4% to 801,940 units (SEC Form 4)

Chief Medical Officer Lee Chin Hyok covered exercise/tax liability with 45,320 shares, decreasing direct ownership by 14% to 285,680 units (SEC Form 4)

Chief Financial Officer Radford Harlan Baird covered exercise/tax liability with 13,665 shares, decreasing direct ownership by 7% to 190,725 units (SEC Form 4)

$ALLK Leadership Updates

Live Leadership Updates

Allakos Appoints Neil Graham to its Board of Directors

Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors

Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors

$ALLK Financials

Live finance-specific insights

Allakos Announces a Restructuring to Focus on Development of AK006

Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints

Recent Analyst Ratings for
$ALLK

$ALLK
Analyst Ratings

$ALLK
Press Releases

$ALLK
Market Insights

$ALLK
Large Ownership Changes

$ALLK
SEC Filings

$ALLK
Insider Trading

$ALLK
Leadership Updates

$ALLK
Financials